COMMUNIQUÉS West-GlobeNewswire

Inari Medical Announces Chief Financial Officer Retirement and Succession Plan

30/07/2024 - 22:10

Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company [...]

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

30/07/2024 - 22:10

ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ [...]

FibroGen to Report Second Quarter 2024 Financial Results

30/07/2024 - 22:07

SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference [...]

Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024

30/07/2024 - 22:05

CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational [...]

Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024

30/07/2024 - 22:05

FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced it will report financial results for the second quarter 2024 after [...]

Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024

30/07/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet [...]

Glass House Brands to Host Second Quarter 2024 Conference Call on August 13, 2024

30/07/2024 - 22:05

LONG BEACH, Calif. and TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company” (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest- [...]

Inari Medical Reports Second Quarter 2024 Financial Results

30/07/2024 - 22:05

IRVINE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]

Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

30/07/2024 - 22:05

SILVER SPRING, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced that it will release its second quarter 2024 [...]

Iridex to Report Second Quarter 2024 Financial Results on August 8, 2024

30/07/2024 - 22:05

MOUNTAIN VIEW, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30/07/2024 - 22:05

Pamrevlumab arm of the Precision Promise SM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as [...]

Stryker reports second quarter 2024 operating results

30/07/2024 - 22:05

Portage, Michigan, July 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2024: Second Quarter Results Reported net sales increased 8.5% to $5.4 billion Organic net [...]

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

30/07/2024 - 22:01

Confirming cash runway guidance into 2026 ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and [...]

Teknova to Report Second Quarter 2024 Financial Results on August 13, 2024

30/07/2024 - 22:01

HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]

Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45

30/07/2024 - 22:01

TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600, [...]

Replimune to Present at Two Upcoming Investor Conferences

30/07/2024 - 22:01

WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced [...]

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

30/07/2024 - 22:00

JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of [...]

Pacira BioSciences Reports Second Quarter 2024 Financial Results

30/07/2024 - 22:00

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative [...]

ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties

30/07/2024 - 18:04

PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists from ADvantage [...]